IBHS Joins Nation'sLargest Hail Study in 40 Years as ICECHIP Launches with Media Field Day
BOULDER, Colo., May 13, 2025 /PRNewswire/ -- The National Science Foundation-funded ICECHIP project—"In-situ Collaborative Experiment for the Collection of Hail In the Plains"—invites members of the media to an exclusive Media Field Day to kick off the largest hail-focused field campaign in the U.S. in more than 40 years.
The ICECHIP Media Field Day will provide firsthand access to live weather demonstrations, storm-tracking tools and interviews with leading atmospheric scientists. The project brings together 15 U.S. institutions and four international partners to study hailstorms across the Central Plains and the Front Range of the Rocky Mountains.
Hail is the most consistently damaging hazard associated with severe thunderstorms, generating over $35 billion in losses in the U.S. last year alone and affecting homeowners, businesses, aviation, agriculture, transportation and more. This six-week field campaign aims to transform the understanding of hail by collecting unprecedented field data - advancing hail detection, improving forecast models and strengthening public warning systems.
MEDIA FIELD DAY HIGHLIGHTS:
Exclusive media access from 1:00–2:00 PM MT
One-on-one questions and interviews with Scientists and team experts
Live public demonstrations from 2:00–4:00 PM MT featuring:
Opening remarks and project overview (2:00–2:15 PM MT)
Weather balloon launch
Doppler on Wheels (DOW) vehicles and mobile mesonets
Hail measurement systems
Radiometers and UAS (large drones)
Online Media Kit: https://www.eol.ucar.edu
Where ICECHIP Goes: The mobile research campaign will continue through June 30th, 2025, and span hail-prone regions across the Plains gathering observations on a wide variety of hailstorms.
Principal Investigators Rebecca Adams-Selin Atmospheric and Environmental Research (Lead PI)John Allen Central Michigan University Victor Gensini Northern Illinois UniversityAndrew Heymsfield National Center for Atmospheric Research
Steering CommitteeBrian Argrow University of Colorado BoulderIan Giammanco Insurance Institute for Business & Home Safety (IBHS)Karen Kosiba University of Alabama HuntsvilleMatthew Kumjian Pennsylvania State UniversityJoshua Wurman University of Alabama Huntsville
For a full list of collaborators and partners, click here.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ibhs-joins-nations-largest-hail-study-in-40-years-as-icechip-launches-with-media-field-day-302453815.html
SOURCE Insurance Institute for Business & Home Safety; Atmospheric and Environmental Research (AER)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 hours ago
- Yahoo
Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
JUPITER, Fla., Aug. 19, 2025 /PRNewswire/ -- Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) program. The funding will support Myosin Therapeutic's Phase I STAR-GBM dose escalation and expansion trial of MT-125, a first-in-class novel small molecule therapeutic being evaluated in patients with newly diagnosed, MGMT unmethylated glioblastoma. Glioblastoma remains among the most lethal cancers, with median survival measured in months. MT-125 targets non-muscle myosin II, a critical driver of tumor cell invasion, proliferation and treatment resistance, representing a novel therapeutic approach that is distinct from existing standards of care. The STAR-GBM trial will assess the safety, tolerability, and pharmacokinetics of MT-125 in this patient population with significant unmet need. Exploratory endpoints include measures of efficacy, including progression-free survival and overall survival. The NCI SBIR program is one of the most competitive federal funding mechanisms for cancer-focused innovation, providing support to small businesses with technologies that have strong scientific merit, commercial potential, and a clear path to clinical impact. Bridge Awards, which require that matching funds from private capital be raised first, are reserved for companies with promising, later-stage projects that have already demonstrated significant technical progress and the potential to attract substantial private investment. "The NCI Bridge Award was perfectly timed to support our STAR-GBM trial, for which patient enrollment is set to begin in November," said Dr. Courtney Miller, co-founder and CEO of Myosin Therapeutics. "It will enable us to generate the data needed to position the program for later-stage development, potential partnerships, and future expansion into a wider range of patients. Our ultimate goal is to deliver a transformative treatment option for patients who currently face limited or inadequate therapeutic choices." About Myosin TherapeuticsMyosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of The Wertheim UF Scripps Institute (formerly Scripps Research, Florida). The company is focused on developing therapies for neuroscience and oncology indications using a platform that targets molecular nanomotor proteins. For more information, visit Contact: contact@ View original content to download multimedia: SOURCE Myosin Therapeutics Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 hours ago
- Yahoo
TransCelerate and FDA Collaborate to Advance Use of Pragmatic Elements in Clinical Trials
New Summary Report and Resource Guide Highlight Opportunities to Integrate Research into Routine Care and Enable Broader Trial Participation PHILADELPHIA, Aug. 19, 2025 /PRNewswire/ -- TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying clinical research, today announced the release of a summary report from a tabletop exercise conducted with the U.S. Food and Drug Administration's (FDA) CDER Center for Clinical Trial Innovation (C3TI), along with the newly published resource, Getting Started with Embedded Pragmatic Trials: A Resource Guide. Held in December 2024, the exercise convened more than 30 pharmaceutical R&D leaders from TransCelerate member companies and eight FDA offices to identify actionable opportunities to scale the use of pragmatic elements in clinical trials to enable more research to be conducted at the point of care. Pragmatic trials offer simplified designs, leverage routine care settings, and reach broader, more representative patient populations—making them well-suited to address public health challenges and areas of significant unmet clinical need. "Collaborative efforts like this help surface practical considerations for embedding clinical research into routine care," said Rob DiCicco, Vice President of Portfolio Management at TransCelerate. "It also highlights the value of FDA's Streamlined Trials Embedded in clinical Practice (STEP) initiative in supporting innovative trial designs that can improve patient access and generate reliable evidence from real-world care settings." TransCelerate's Embedded Pragmatic Trials initiative aims to accelerate the adoption of these trial designs by building awareness, engaging in productive dialogue with regulatory authorities and other stakeholders, and offering practical tools to guide implementation. "Pragmatic trials have the potential to transform how clinical research is conducted – bringing trials closer to where care is delivered and expanding patient access to clinical trials," said Kevin Bugin, Head of Global Regulatory Policy at Amgen and executive sponsor of TransCelerate's Embedded Pragmatic Trials initiative. "This exercise represents a critical step toward enabling this vision, and we are grateful for the FDA's partnership and engagement." As part of the informal, non-binding exercise, TransCelerate presented a hypothetical case study evaluating a new indication for a post-approval medication. The clinical trial design incorporated several pragmatic elements, including simplified data collection, broad eligibility criteria, and integration with electronic health records (EHRs). Key themes from the session include: Design and Oversight Considerations: The value of hybrid trial designs, fit-for-purpose investigator and third-party oversight frameworks, and early feasibility assessments to ensure data readiness and regulatory alignment. Data Integrity and Endpoint Alignment: Opportunities to improve data quality by integrating EHR data with thoughtful quality-by-design (QbD) approaches and clarified endpoint definitions. Value of Broad Agency Collaboration: The need for aligned expectations regarding endpoint selection, adjudication, blinding and inspection priorities across multiple FDA offices. Operational Efficiency and Privacy: Exploration of computational methods to ensure data integrity while preserving patient privacy during inspections. In parallel with the tabletop exercise, TransCelerate has released Getting Started with Embedded Pragmatic Trials: A Resource Guide, a robust tool designed to build understanding of embedded pragmatic trials and provide practical guidance for successful implementation. The guide identifies resources to help stakeholders navigate the design and implementation of trials that incorporate pragmatic elements such as simplified data collection, broad eligibility criteria, and EHR integration. Looking Ahead TransCelerate will continue to collaborate with global regulators, sponsors, and stakeholders to: Advance understanding and adoption of pragmatic trials through real-world case studies, tools, and shared learnings. Clarify operational distinctions between pragmatic and traditional trial models. Identify infrastructure-ready geographies to support implementation at scale. The full report, Enabling the Implementation of Pragmatic Elements at Scale: Summary Report from an FDA and TransCelerate Tabletop Exercise, is available here: To learn more about TransCelerate's Embedded Pragmatic Trials Initiative, visit: About TransCelerate BioPharma BioPharma (TransCelerate) is a nonprofit organization that fosters collaboration across the global biopharmaceutical research and development community to simplify clinical trials and help bring new treatments to patients faster, safer, and more efficiently. Headquartered in the Philadelphia area, TransCelerate has 20 member companies and a robust portfolio of initiatives focused on transforming connectivity, enabling information sharing and reuse, and driving innovative trial designs. For more information, please visit View original content to download multimedia: SOURCE TransCelerate BioPharma
Yahoo
18 hours ago
- Yahoo
Accelerating Data Entry for Non-GLP Pathology Studies, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how streamlined workflows and intuitive interfaces help pathologists reduce time spent on slide review and data capture — freeing up hours for deeper analysis. Attendees will see how built-in checks, standardized terminology and smart glossaries reduce errors and ensure pathology data can be trusted throughout the study lifecycle. The featured speakers will share how efficient, flexible tools can support non-GLP pathology studies without sacrificing structure — helping study directors manage timelines, staff and results more effectively. TORONTO, Aug. 19, 2025 /PRNewswire/ -- Pathologists and study directors in nonclinical research are under increasing pressure to deliver high-quality results faster, without compromising data integrity. Traditional, manual methods of data entry are too slow, error-prone and unstructured to meet the demands of today's fast-paced, high-throughput labs. That's why modern pathology teams are turning to efficient, standardized digital tools to accelerate workflows, reduce human error and improve overall productivity in conducting non-GLP pathology studies. Another goal of an optimized pathology workflow is about transforming how non-GLP pathology studies are managed, recorded and scaled for future success. With smarter digital systems, labs can gain immediate efficiency while laying the groundwork for regulatory readiness down the road. In this webinar, the featured speakers will explore how pathology teams can modernize their approach to study management with tools designed specifically for fast, intuitive and reliable histopathology workflows. For teams aiming to optimize current non-GLP processes or prepare for future GLP compliance, this session will offer practical insights to support confident progress. Join the pathology experts as they demonstrate how digital tools and workflows can: Reduce slide review and data entry time by up to 20% using streamlined digital workflows built for non-GLP environments Improve data integrity and accessibility with structured study management tools offering a single source of truth for moderated access and editing. Streamline glossary management with integrated terminology support based on CDISC ontology and intelligent search features. Manage non-GLP studies more efficiently through flexible, user-friendly platforms that support better team coordination and faster study completion Prepare labs for future GLP compliance by adopting digital tools that align with industry standards and regulatory expectations Register for this webinar to learn how digital transformation can drive efficiency and readiness across pathology studies, supporting pathologists, study directors, lab managers and more. Join experts from Instem, Chris Nichols, Senior Director; and Chris Hunter, Product Manager, Pathology Study Management, for the live webinar on Friday, September 5, 2025, at 10am EDT (4pm CEST/EU-Central). For more information, or to register for this event, visit Accelerating Data Entry for Non-GLP Pathology Studies. ABOUT XTALKS Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit For information about hosting a webinar visit Contact:Vera KovacevicTel: +1 (416) 977-6555 x371Email: vkovacevic@ View original content to download multimedia: SOURCE Xtalks Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
